Apr 30, 2026 05:00PM
Feb 5, 2026 05:00PM
Jan 13, 2026 05:00PM
Jan 13, 2026 05:00PM
Jan 9, 2026 07:58AM
Dec 17, 2025 05:00PM
Dec 17, 2025 05:00PM Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Oct 30, 2025 05:00PM
Oct 16, 2025 08:00AM
Oct 16, 2025 08:00AM
Jul 31, 2025 05:00PM
Jul 15, 2025 05:00PM
Jul 15, 2025 05:00PM
May 1, 2025 05:03PM Aptar Reports First Quarter 2025 Results
Apr 16, 2025 08:02AM
Apr 16, 2025 08:00AM
Feb 6, 2025 05:17PM
Oct 24, 2024 05:00PM
Sep 23, 2024 05:01PM
Sep 23, 2024 05:00PM
Aug 15, 2024 05:00PM Aptar’s Nasal Unidose System to Deliver neffy® (epinephrine nasal spray), the First and Only FDA-Approved Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Jul 25, 2024 05:00PM
Apr 25, 2024 05:00PM
Feb 8, 2024 05:00PM
Dec 4, 2023 08:37AM
Dec 4, 2023 08:30AM
Sep 22, 2022 08:30AM
Oct 25, 2021 08:30AM First Nasally-Administered Pharmaceutical Treatment for Dry Eye Disease Approved by US FDA with Aptar’s Nasal Pump System
Apr 6, 2021 07:04AM
Apr 6, 2021 07:00AM
Feb 15, 2021 05:00PM
May 8, 2020 08:40AM
May 8, 2020 08:30AM
Apr 3, 2020 05:58PM
Feb 20, 2020 05:00PM Aptar Reports Fourth Quarter and Annual Results; Recaps Year of Pharma Services Acquisitions and Multiple New Drug Delivery Launches; Highlights Strategic Steps to Strengthen Beauty Business
Dec 9, 2019 08:32AM
Dec 9, 2019 08:30AM
Oct 22, 2019 05:00PM
Oct 21, 2019 09:30AM
Sep 10, 2019 07:30AM
Jul 25, 2019 10:31AM
Mar 20, 2019 09:28AM AptarGroup's (ATR) Biodose Approval Highlights Pipeline Opportunities - Baird
Mar 18, 2019 05:00PM
Jan 18, 2019 08:30AM
May 2, 2017 05:00PM
Mar 22, 2017 05:00PM

322,245 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All